About Amniotics™

History

Amniotics™, formerly Longboat Amniotics, was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue relevant neonatal quality mesenchymal stem cells (MSCs). Researchers and founders of the company, pediatrician Marcus Larsson, obstetrician Andreas Herbst and stem cell specialist Niels-Bjarne Woods discovered a new type of stem cells in amniotic fluid that has unique properties for applications in regenerative medicine.

In the summer of 2019, the company raised 20 MSEK for the validation of our MSCs in preclinical models for lung disease as well as for the completion and process validation of the GMP manufacturing facility. With the new GMP facilities operational in early 2020, Amniotics™ is now looking to establish strategic partnerships with companies that are interested in developing stem-cell-based therapies targeting diseases with unmet needs.

Vision

To contribute to the successful treatment of human diseases by providing the very best stem cell for medical applications. We are devoted to developing innovative life-changing and regenerative treatments for patients.

Mission

Deliver safe and effective innovative therapies to patients with unmet medical needs.

Strategy

The strategy is to develop treatments for diseases with severe inflammatory and fibrotic components, where tissue-relevant stem cells can be expected to have an impact and be life-changing treatments.

The objective is to successfully conduct and complete planned clinical trials with our tissue-relevant MSCs.

Amniotics™ is presently producing technical batches of our lung-appropriate cells and qualifying the premises for ATMP production and GMP inspection. With the results from our preclinical studies and the characterization of the quality attributes of the cells (sterility, stability, identity, purity, potency, injectability), we are moving towards clinical trials with speed, with a focus set for treatment of COVID-19.

Core Values

At Amniotics™, we aim to positively impact the lives of patients and their families with severe diseases by developing innovative therapies. With our novel treatments in development, we strive to help as many patients as possible as fast as possible.

Management Team

Kåre Engkilde, PhD

Kåre Engkilde, PhD

Chief Executive Officer

  • MSc in Chemical Engineering and Biotechnology from Denmark’s Technical University, followed by a PhD in Immunology at Københavns Universitet, Denmark
  • Joined in 2019
  • Previously at Novo Nordisk, LEO Pharma, Bioneer, Agilent Technologies
Jan Talts, PhD

Jan Talts, PhD

Chief Operating Officer

  • PhD in Animal Physiology, Uppsala University, Sweden
  • Joined in 2017
  • Previously at Xintela AB, Region Skåne, University of Copenhagen and the Royal Veterinary University, Denmark and Lund University, Sweden
Helle Størum

Helle Størum

Head of Business Development

 Jonas Lundahl

Jonas Lundahl

Director Clinical/Regulatory Affairs

Our Team

Sidonie Karlsson, MSc

Sidonie Karlsson, MSc

Production Manager

  • BSc in Biochemistry and Organic Chemistry Engineering (Ecole Nationale Supérieure de Chimie de Montpellier, France), MSc in Biochemistry (Lund University)
  • Joined in 2019
  • Previously 22+ years of experience in the industry with AstraZeneca (UK), Novo Nordisk, BioInvent International AB, PlantVision AB, Galenica AB, Straumann
Shalini Prabhu, PhD

Shalini Prabhu, PhD

Production Scientist

  • PhD in Molecular Biology from Bangalore University (India)
  • Joined in 2017
  • Previously 13+ years in GMP regulated industry at Metahelix and Sri Raghavendra Biotechnologies
Sofia Lindegård, MSc

Sofia Lindegård, MSc

Production Scientist

  • MSc in Medical Biology (Lund University)
  • Joined in 2018
  • Previously at Anicura
Martina Johannesson, PhD

Martina Johannesson, PhD

Quality Control Scientist

  • MSc in Molecular Biology (Lund University) in collaboration with Camurus AB and Ph.D. in Medical Science (Lund University).
  • Joined in 2019
  • Previously at Xintela AB, Spago Nanomedical AB, Swedish Socialstyrelsen (publ), and VitroSorb AB

Board

Christer Fåhraeus, PhD

Christer Fåhraeus, PhD

Board Chairman

  • Member since 2015
  • Founder of several international life science and technology companies, such as Cellavision AB, Precise Biometrics AB, and Anoto Group AB
  • Currently Board member of Cellavision AB (publ), EQL Pharma AB (publ), Lund University innovation AB, the Tech Transfer Office at Lund University, and Reccan Diagnostics AB.
  • Chairman of FlatFrog Laboratories AB and Respiratorius AB (publ)
  • CEO of EQL Pharma AB (publ).
Marcus Larsson, MD, PhD

Marcus Larsson, MD, PhD

Board member

  • Co-founder, Member since 2015
  • PhD (Lund University)
  • CEO of the company during the first two years (2015- Jun 2017)
Anders Månsson, MBA

Anders Månsson, MBA

Board member

  • BSc in Business & Economics (Lund University), Executive MBA (Business School Lausanne, Switzerland).
  • Member since 2015 with a break when he worked as Amniotics AB’s CEO from Jun 2017 to May 2019.
  • Previously at Meda Pharma (now Mylan), Ferring Pharmaceuticals, and LEO Pharma
  • Former Member of the board of Respiratorius AB (Publ.); Industrial Advisor of Ratos AB, and Chairman of the Board of CanImGuide Therapeutics AB,
  • Currently Member of the Board of EQL Pharma AB (publ) and CEO of RhoVac
Lars Stigsson, MSc

Lars Stigsson, MSc

Board member

  • Member since 2019
  • MSc in Chemical Engineering (Lund University)
  • Founder, among others, of SunPine AB and Sun Carbon AB.  Co-founder of BioShare and TreeToTextile AB
  • Inventor in over 20 patent series relating to biofuels, innovative textile fiber processes and forest industry biorefinery technologies
  • Awarded with the Polhem Price in 2018
WP to LinkedIn Auto Publish Powered By : XYZScripts.com